PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11122013-8 2000 Co-incubation with metabolic inhibitors, actinomycin D and cycloheximide, revealed that the early induction of TGF-beta1 mRNA by 1,25(OH)2D3 is dependent on de novo RNA synthesis, but not on RNA stabilization or protein synthesis. Cycloheximide 59-72 transforming growth factor beta 1 Homo sapiens 111-120 11453539-6 2001 When TGF-beta replaced cycloheximide in the subsequent 8-hour treatment, TGF-beta inhibited this bFGF-enhanced DNA-Ets complex formation. Cycloheximide 23-36 transforming growth factor beta 1 Homo sapiens 73-81 11453539-7 2001 When TGF-beta and cycloheximide were simultaneously added in the subsequent 8-hour treatment, the inhibitory effect of TGF-beta on bFGF-enhanced DNA-Ets complex formation was completely abolished. Cycloheximide 18-31 transforming growth factor beta 1 Homo sapiens 119-127 11138844-5 2000 Cycloheximide inhibited TGF-beta1-mediated reduction of beta2-adrenoceptor mRNA and protein, whilst alone caused induction of beta2-adrenoceptor mRNA without any effect on receptor number. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 24-33 10896788-9 2000 Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 100-109 10896788-9 2000 Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 100-108 9660180-4 1998 There was an up to fivefold increase in 5-LO primary transcripts by TGFbeta and calcitriol, which could be inhibited by cycloheximide. Cycloheximide 120-133 transforming growth factor beta 1 Homo sapiens 68-75 10385601-7 1999 In contrast, RNI-induced TGF-beta1 release was unaffected by DRB and blunted by the protein synthesis inhibitor cycloheximide, suggesting the involvement of translational and post-translational mechanisms. Cycloheximide 112-125 transforming growth factor beta 1 Homo sapiens 25-34 10757810-6 2000 In at least five cases, the TGF-beta-induced upregulation was found to be cycloheximide resistant, suggesting the roles of the genes in the TGF-beta-induced primary responses. Cycloheximide 74-87 transforming growth factor beta 1 Homo sapiens 28-36 10757810-6 2000 In at least five cases, the TGF-beta-induced upregulation was found to be cycloheximide resistant, suggesting the roles of the genes in the TGF-beta-induced primary responses. Cycloheximide 74-87 transforming growth factor beta 1 Homo sapiens 140-148 10600887-1 1999 Transforming growth factor-beta (TGF-beta) stimulates alpha(1)(I) collagen mRNA synthesis in human lung fibroblasts through a mechanism that is partially sensitive to cycloheximide and that may involve synthesis of connective tissue growth factor (CTGF). Cycloheximide 167-180 transforming growth factor beta 1 Homo sapiens 0-31 10600887-1 1999 Transforming growth factor-beta (TGF-beta) stimulates alpha(1)(I) collagen mRNA synthesis in human lung fibroblasts through a mechanism that is partially sensitive to cycloheximide and that may involve synthesis of connective tissue growth factor (CTGF). Cycloheximide 167-180 transforming growth factor beta 1 Homo sapiens 33-41 10521580-5 1999 The TGF-beta1, GGF(2) and forskolin dependent reduction in NT-3 mRNA levels involved a destabilization of transcripts which was antagonised by co-treatment with cycloheximide. Cycloheximide 161-174 transforming growth factor beta 1 Homo sapiens 4-13 9660180-7 1998 Addition of cycloheximide together with the second inducer inhibited only the TGFbeta but not the calcitriol effects, which indicated that there is a direct stimulation of 5-LO transcription by calcitriol in the presence of TGFbeta-induced proteins. Cycloheximide 12-25 transforming growth factor beta 1 Homo sapiens 78-85 9660180-7 1998 Addition of cycloheximide together with the second inducer inhibited only the TGFbeta but not the calcitriol effects, which indicated that there is a direct stimulation of 5-LO transcription by calcitriol in the presence of TGFbeta-induced proteins. Cycloheximide 12-25 transforming growth factor beta 1 Homo sapiens 224-231 9660180-12 1998 The effects of both TGFbeta and calcitriol on transcript elongation and maturation were inhibited by cycloheximide. Cycloheximide 101-114 transforming growth factor beta 1 Homo sapiens 20-27 9537840-6 1998 Cycloheximide did not block the effects of TGF-beta1 or FGF-2 on GFAP mRNA levels, but blocked the inhibitory effects of FGF-2 on the TGF-beta1-mediated increase in GFAP expression. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 134-143 9258340-11 1997 Simultaneous treatment with Chs and cycloheximide (Cxm) resulted in a superinduction of TGF-beta 1 mRNA by 88 +/- 23% (n = 4, P < 0.05), which was abrogated by preexposure to Act D. In contrast, the induction of collagenase mRNA by Chs was totally blocked by Cxm, indicating that the Cxm-mediated superinduction is selective and that protein synthesis is required for induction of this mRNA. Cycloheximide 36-49 transforming growth factor beta 1 Homo sapiens 88-98 9322956-4 1997 The blockade of synthesis of proteins with either cycloheximide or puromycin for 24 h prevented the inhibitory effect of TGFbeta1 on somatostatin mRNA. Cycloheximide 50-63 transforming growth factor beta 1 Homo sapiens 121-129 9259353-10 1997 Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins. Cycloheximide 12-25 transforming growth factor beta 1 Homo sapiens 140-149 9258340-11 1997 Simultaneous treatment with Chs and cycloheximide (Cxm) resulted in a superinduction of TGF-beta 1 mRNA by 88 +/- 23% (n = 4, P < 0.05), which was abrogated by preexposure to Act D. In contrast, the induction of collagenase mRNA by Chs was totally blocked by Cxm, indicating that the Cxm-mediated superinduction is selective and that protein synthesis is required for induction of this mRNA. Cycloheximide 51-54 transforming growth factor beta 1 Homo sapiens 88-98 9145908-8 1997 The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression. Cycloheximide 28-41 transforming growth factor beta 1 Homo sapiens 155-164 9209893-7 1997 Cycloheximide treatment blocked this TGF-beta 1 protein induction indicating de novo protein synthesis of TGF-beta 1 from keratinocytes induced by UVB. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 37-47 9209893-7 1997 Cycloheximide treatment blocked this TGF-beta 1 protein induction indicating de novo protein synthesis of TGF-beta 1 from keratinocytes induced by UVB. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 106-116 8622626-8 1996 Cycloheximide (10 micrograms/ml) pretreatment abolished the TGF-beta 1 effect, indicating that de novo protein synthesis was required for receptor downregulation. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 60-70 9075824-4 1997 Increases in alpha-thrombin-induced TGF-beta1 message expression were insensitive to cycloheximide, but sensitive to actinomycin D. Cycloheximide 85-98 transforming growth factor beta 1 Homo sapiens 36-45 8914021-9 1996 Stimulation of TGF-beta 1 synthesis by IL-1 beta in D-glucose primed cells was inhibited by cycloheximide but not by actinomycin-D. Cycloheximide 92-105 transforming growth factor beta 1 Homo sapiens 15-25 8407955-2 1993 In this study, differential hybridization was used to screen a cDNA library constructed from human mammary carcinoma MDA-468 cells that were stimulated with transforming growth factor beta-1 (TGF-beta 1) in the presence of cycloheximide. Cycloheximide 223-236 transforming growth factor beta 1 Homo sapiens 157-190 8519657-7 1995 The accumulation of TAM-induced TGF-beta 1 mRNA was increased by cycloheximide, but was not affected by 17 beta-oestradiol. Cycloheximide 65-78 transforming growth factor beta 1 Homo sapiens 32-42 7741713-5 1995 The stimulations by PDGF-BB and TGF-beta 1 were partly dependent on protein synthesis, since parts of the effects were inhibited by cycloheximide; in contrast, the effects mediated by PMA were not. Cycloheximide 132-145 transforming growth factor beta 1 Homo sapiens 32-42 7882362-8 1995 Analyses of the vitamin D3 responses in the presence of cycloheximide or actinomycin D indicated that the TGF-beta 1 mRNA induction was dependent on both protein and RNA synthesis. Cycloheximide 56-69 transforming growth factor beta 1 Homo sapiens 106-116 7852844-3 1995 Under all three conditions, both forms of TGF-beta (20 ng/ml) induced a two- to fourfold increase in C3 concentration in monocyte supernatants harvested after 2 or 5 days of cell culture, an effect that was abrogated by cycloheximide. Cycloheximide 220-233 transforming growth factor beta 1 Homo sapiens 42-50 21567024-6 1994 The apoptosis and increased expression of TGF-beta 1 could be completely blocked;by the addition of cycloheximide given within 12 h of RA treatment. Cycloheximide 100-113 transforming growth factor beta 1 Homo sapiens 42-52 8085941-4 1994 In the presence of cycloheximide, the effect of TGF-beta 1 on CYPIA1 mRNA disappeared. Cycloheximide 19-32 transforming growth factor beta 1 Homo sapiens 48-58 8822345-4 1996 The autostimulation of TGF-beta 1 mRNA was nullified by cycloheximide treatment of the cells. Cycloheximide 56-69 transforming growth factor beta 1 Homo sapiens 23-33 7590899-3 1995 A 20 min incubation with TGF-beta was sufficient to induce adherence and this could be inhibited by cycloheximide. Cycloheximide 100-113 transforming growth factor beta 1 Homo sapiens 25-33 7721958-9 1995 In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis. Cycloheximide 19-32 transforming growth factor beta 1 Homo sapiens 34-42 7721958-9 1995 In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis. Cycloheximide 19-32 transforming growth factor beta 1 Homo sapiens 131-139 7964554-10 1994 Northern blot analysis of MEPM cells treated with TGF beta 1 revealed that steady-state levels of mRNA encoding for procollagen alpha 1 (I) and alpha 1 (III) were increased and that these effects were ablated by cycloheximide but not actinomycin. Cycloheximide 212-225 transforming growth factor beta 1 Homo sapiens 50-60 8141314-8 1994 The protein synthesis inhibitor cycloheximide abolished the effect of TGF-beta 1 on both cAMP accumulation and on beta-adrenergic receptor number, indicating that protein synthesis is involved. Cycloheximide 32-45 transforming growth factor beta 1 Homo sapiens 70-80 8407955-2 1993 In this study, differential hybridization was used to screen a cDNA library constructed from human mammary carcinoma MDA-468 cells that were stimulated with transforming growth factor beta-1 (TGF-beta 1) in the presence of cycloheximide. Cycloheximide 223-236 transforming growth factor beta 1 Homo sapiens 192-202 8427857-7 1993 Induction of PDGF-A and TGF-beta 1 was attenuated by cycloheximide, but bFGF induction was unaffected. Cycloheximide 53-66 transforming growth factor beta 1 Homo sapiens 24-34 1939646-8 1991 The increase in TGF-beta 1 mRNA levels by dexamethasone was further potentiated two to threefold by cycloheximide, suggesting that the steroid effect may be due to inhibition of the synthesis of proteins that decrease TGF-beta 1 gene transcription or the stability of its transcripts. Cycloheximide 100-113 transforming growth factor beta 1 Homo sapiens 16-26 1327512-7 1992 The emergence of an active form of TGF-beta was also observed in cultures of Type A tumor cells, the protein synthesis of which was almost completely inhibited by pretreatment with cycloheximide. Cycloheximide 181-194 transforming growth factor beta 1 Homo sapiens 35-43 1655420-6 1991 The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen. Cycloheximide 32-45 transforming growth factor beta 1 Homo sapiens 145-155 8054703-6 1993 The potentiation of IL6 mRNA by TGF-beta 1 required de novo synthesis of an intermediate protein since treatment with cycloheximide abrogated the amount of mRNA enhanced by TGF-beta 1 without affecting IL1 alpha-driven mRNA production. Cycloheximide 118-131 transforming growth factor beta 1 Homo sapiens 32-42 8054703-6 1993 The potentiation of IL6 mRNA by TGF-beta 1 required de novo synthesis of an intermediate protein since treatment with cycloheximide abrogated the amount of mRNA enhanced by TGF-beta 1 without affecting IL1 alpha-driven mRNA production. Cycloheximide 118-131 transforming growth factor beta 1 Homo sapiens 173-183 1567364-4 1992 In contrast, the stimulatory effect of transforming growth factor-beta 1 reached a maximum after 24 h. The stimulatory effect of PDGF-BB was inhibited by cycloheximide. Cycloheximide 154-167 transforming growth factor beta 1 Homo sapiens 39-72 1939646-8 1991 The increase in TGF-beta 1 mRNA levels by dexamethasone was further potentiated two to threefold by cycloheximide, suggesting that the steroid effect may be due to inhibition of the synthesis of proteins that decrease TGF-beta 1 gene transcription or the stability of its transcripts. Cycloheximide 100-113 transforming growth factor beta 1 Homo sapiens 218-228 2968288-6 1988 Induction of cyclooxygenase by EGF and TGF-beta also was prevented by cycloheximide but not by actinomycin D. Cycloheximide 70-83 transforming growth factor beta 1 Homo sapiens 39-47 1655396-10 1991 Cycloheximide, an inhibitor of protein synthesis, prevents the effect of CT and 12-O-tetradecanoyl phorbol-13-acetate on TGF-beta 1 mRNA expression in JEG-3 cells, suggesting that a protein mediator may be involved in the transduction of their effects. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 121-131 1650483-8 1991 Chemoattraction by both fMet-Leu-Phe and TGF-beta 1 was inhibited by cycloheximide and actinomycin D. Cycloheximide 69-82 transforming growth factor beta 1 Homo sapiens 41-51 1649834-6 1991 The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels. Cycloheximide 110-123 transforming growth factor beta 1 Homo sapiens 83-93 1649834-6 1991 The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels. Cycloheximide 110-123 transforming growth factor beta 1 Homo sapiens 197-207 1770016-7 1991 Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene. Cycloheximide 129-142 transforming growth factor beta 1 Homo sapiens 0-31 1770016-7 1991 Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene. Cycloheximide 129-142 transforming growth factor beta 1 Homo sapiens 33-41 1770016-7 1991 Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene. Cycloheximide 129-142 transforming growth factor beta 1 Homo sapiens 160-168 1995305-10 1991 The inclusion of cycloheximide in the protocol indicated that TGF beta induction of collagen alpha 1 (IV) mRNA was signaled by proteins already present in the cells but that TGF beta required the synthesis of a protein(s) to fully induce expression of fibronectin and laminin B1 mRNA. Cycloheximide 17-30 transforming growth factor beta 1 Homo sapiens 62-70 2046332-6 1991 Cycloheximide experiments provided evidence that the TGF-beta 1-elicited upregulation of the expression of the fibronectin gene is, but that of type IV collagen is not, entirely dependent on protein synthesis, suggesting two different mechanisms for enhancement of gene expression. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 53-63 1698783-4 1990 The stimulatory effects of TGF-beta were prevented by the inhibitors of protein synthesis and DNA transcription, cycloheximide, or actinomycin D, respectively. Cycloheximide 113-126 transforming growth factor beta 1 Homo sapiens 27-35 1972706-10 1990 Maximal induction of transglutaminase Type II mRNA occurred between 18 and 24 h. The increase in Type II transglutaminase mRNA levels was blocked by the presence of cycloheximide, suggesting that this increase in mRNA by TGF-beta 1 is dependent on protein synthesis. Cycloheximide 165-178 transforming growth factor beta 1 Homo sapiens 221-231 17209135-4 2007 The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126. Cycloheximide 241-254 transforming growth factor beta 1 Homo sapiens 54-62 3422640-2 1988 TGF-beta regulates the level and molecular size of these proteoglycans by acting simultaneously at two levels: it elevates the biosynthetic rate of the 45-kDa proteoglycan core protein in a cycloheximide- and actinomycin D-sensitive manner, and it induces an increase in the molecular mass of the glycosaminoglycan chains. Cycloheximide 190-203 transforming growth factor beta 1 Homo sapiens 0-8 3496959-9 1987 Treatment of the cells with TGF beta enhances the EGF-dependent superinduction of EGF receptor mRNA produced by cycloheximide, suggesting that the stimulatory action of TGF beta does not depend on continuous protein synthesis. Cycloheximide 112-125 transforming growth factor beta 1 Homo sapiens 28-36 3496959-9 1987 Treatment of the cells with TGF beta enhances the EGF-dependent superinduction of EGF receptor mRNA produced by cycloheximide, suggesting that the stimulatory action of TGF beta does not depend on continuous protein synthesis. Cycloheximide 112-125 transforming growth factor beta 1 Homo sapiens 169-177 34031187-9 2021 These results suggest that TGF-beta1 activates Rho/pMLC2 through an indirect mechanism which was confirmed by sensitivity to cycloheximide treatment. Cycloheximide 125-138 transforming growth factor beta 1 Homo sapiens 27-36 21303922-9 2011 Consistent with a requirement for de novo induction of JunB protein, cycloheximide pretreatment inhibited TGF-beta1 induction of Itgbeta6 mRNA. Cycloheximide 69-82 transforming growth factor beta 1 Homo sapiens 106-115 20547156-7 2010 The induction of TGFbeta1 was independent of a change in transcription, but it depended on cycloheximide-inhibited translation. Cycloheximide 91-104 transforming growth factor beta 1 Homo sapiens 17-25 25870205-5 2015 Addition of cycloheximide, a transforming growth factor (TGF)-beta inhibitor (SB431542), or a neutralizing antibody against TGF-beta1 attenuated the force-induced expression of SOST and POSTN as well as sclerostin and periostin, indicating a role of TGF-beta1 in the pressure-induced expression of these proteins. Cycloheximide 12-25 transforming growth factor beta 1 Homo sapiens 250-259 23762390-11 2013 Cycloheximide treatment, which inhibits protein synthesis, decreased both the constitutive release of soluble FBLN-1, and TGF-beta1 induced ECM FBLN-1 deposition. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 122-131 20091742-10 2010 In addition, through the use of cycloheximide and the proteasome inhibitor MG132, we showed that hyperosmolarity significantly increased the half-life and inhibited the protein level of TGF-beta RI by polyubiquitination and proteasomal degradation. Cycloheximide 32-45 transforming growth factor beta 1 Homo sapiens 186-194 18252865-7 2008 Similarly, pretreatment with cycloheximide prevented CCL5 or CXCR4 mRNA expression, consistent with the observation that DAMGO induction of chemokine and chemokine receptor expression requires newly synthesized TGF-beta1 protein. Cycloheximide 29-42 transforming growth factor beta 1 Homo sapiens 211-220 16541418-8 2006 TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD). Cycloheximide 95-108 transforming growth factor beta 1 Homo sapiens 0-9 16675452-10 2006 Pharmacologic inhibition of translation with cycloheximide attenuated Cited2 down-regulation by TGF-beta. Cycloheximide 45-58 transforming growth factor beta 1 Homo sapiens 96-104 16541418-8 2006 TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD). Cycloheximide 110-113 transforming growth factor beta 1 Homo sapiens 0-9 16353668-6 2005 Inhibition of Sf-1 expression by TGF-beta was abolished by cycloheximide, suggesting that the growth factor inhibitory effect requires ongoing protein synthesis. Cycloheximide 59-72 transforming growth factor beta 1 Homo sapiens 33-41 15770661-6 2005 Stimulation by TGF-beta and PMA were dependent on protein synthesis and their effects were inhibited by cycloheximide. Cycloheximide 104-117 transforming growth factor beta 1 Homo sapiens 15-23 15009103-9 2004 The addition of cycloheximide to the cell cultures strongly inhibited the increase of VEGF proteins in TGF-beta1-stimulated NHFs. Cycloheximide 16-29 transforming growth factor beta 1 Homo sapiens 103-112 12646579-5 2003 TGF-beta 1 induced ADAMTS-2 mRNA approximately 8-fold in MG-63 osteosarcoma cells in a dose- and time-dependent, cycloheximide-inhibitable manner, which appeared to operate at the transcriptional level. Cycloheximide 113-126 transforming growth factor beta 1 Homo sapiens 0-10 12376363-5 2002 Actinomycin D and cycloheximide inhibited TGF-beta1-responsive HO-1 mRNA expression, indicating a requirement for transcription and de novo protein synthesis. Cycloheximide 18-31 transforming growth factor beta 1 Homo sapiens 42-51 12370400-9 2002 Cycloheximide blocked the increase in mRNA at 6 h in both conditions, but also blocked the increase at 24 h with TGF-beta1 plus IL-13. Cycloheximide 0-13 transforming growth factor beta 1 Homo sapiens 113-122 11912247-6 2002 For example, exposure to 1 ng/ml TGF-beta1 for 15 h increased uptake approximately twofold, a response that was attenuated by cycloheximide. Cycloheximide 126-139 transforming growth factor beta 1 Homo sapiens 33-42 11696451-7 2001 Insulin-induced increase in TGF-beta1 concentration was not abrogated by actinomycin D, however, stimulation by insulin, in the presence of cycloheximide led to a dose-dependent decrease in TGF-beta1 production. Cycloheximide 140-153 transforming growth factor beta 1 Homo sapiens 190-199 12140283-3 2002 In PANC-1 cells, TGF-beta1 dramatically stimulated BGN mRNA accumulation through a BGN transcription-independent, cycloheximide-sensitive mechanism and strongly increased the synthesis and release of the proteoglycan form of BGN. Cycloheximide 114-127 transforming growth factor beta 1 Homo sapiens 17-26 11716780-5 2001 The TGF-beta 1-mediated l-proline uptake was inhibited by cycloheximide or actinomycin D. Cycloheximide 58-71 transforming growth factor beta 1 Homo sapiens 4-14